DiaMedica Therapeutics, Inc. DMAC
- Market cap
- $422.2M
- P/E
- 0.0×
Follow DMAC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.90 | 2.19 | 2.46 | 1.70 | 1.87 | 3.00 | 1.12 | 1.27 | 2.14 | 3.19 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 5.25 | 6.90 | 13.77 | 5.93 | 10.43 | 10.88 | 3.94 | 4.75 | 6.41 | 10.42 |
High Price
|
|||
| 7 | 9 | 9 | 9 | 11 | 15 | 16 | 19 | 28 | 35 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 1 | — | — | — | — | — | — | — |
Revenue
|
|||
| 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Gross Margin
|
|||
| (2) | (4) | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) |
EBT
|
|||
| 0.00% | 0.00% | (1,130.80%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| (2) | (4) | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | (1) | (1) |
Depreciation
|
|||
| 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (0.47) | (0.68) | (0.74) | (0.89) | (0.78) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
Earnings/Sh
|
|||
| (0.64) | (0.66) | (0.74) | (0.76) | (0.59) | (0.59) | (0.44) | (0.58) | (0.55) | (0.62) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.64) | (0.66) | (0.74) | (0.76) | (0.59) | (0.59) | (0.44) | (0.58) | (0.55) | (0.62) |
Free CF/Sh
|
|||
| 0.26 | 0.13 | 2.20 | 0.64 | 1.66 | 2.12 | 1.20 | 1.57 | 1.01 | 1.19 |
Book Value/Sh
|
|||
| 5 | 6 | 8 | 12 | 16 | 21 | 26 | 33 | 40 | 47 |
Shares
|
|||
| — | — | 0.00 | — | — | — | — | — | — | — |
PE Ratio
|
|||
| — | — | 0.00 | — | — | — | — | — | — | — |
PS Ratio
|
|||
| — | — | 1.32 | — | — | — | — | — | — | — |
PB Ratio
|
|||
| — | — | 0.00 | — | — | — | — | — | — | — |
EV/Sales
|
|||
| — | — | (1.00) | — | — | — | — | — | — | — |
EV/FCF
|
|||
| (3) | (4) | (6) | (9) | (9) | (12) | (12) | (19) | (22) | (29) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| (3) | (4) | (6) | (9) | (9) | (12) | (12) | (19) | (22) | (29) |
FCF
|
|||
| 1 | 0 | 17 | 8 | 26 | 44 | 32 | 51 | 39 | 55 |
Working Cap'
|
|||
| 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Debt
|
|||
| (2) | (1) | (17) | (8) | (27) | (45) | (33) | (53) | (44) | (60) |
Net Debt
|
|||
| 1 | 1 | 17 | 8 | 26 | 44 | 32 | 51 | 41 | 56 |
Sh' Equity
|
|||
| (212.13%) | (231.84%) | (56.94%) | (77.75%) | (66.18%) | (36.91%) | (34.21%) | (43.77%) | (48.64%) | (60.84%) |
ROA
|
|||
| 0.00% | 0.00% | (1,920.74%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (33,683.33%) | (416.63%) | (64.34%) | (86.43%) | (73.10%) | (38.81%) | (36.06%) | (46.77%) | (53.27%) | (67.68%) |
ROE
|
|||
DiaMedica Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PRTCY PureTech Health PLC Sponsored ADR | $424.0M | 0.0× | Compare |
| PRTA Prothena Corporation plc | $427.1M | 0.0× | Compare |
| AVIR Atea Pharmaceuticals, Inc. | $414.7M | 0.0× | Compare |
| EDIT Editas Medicine, Inc. | $430.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SPRY ARS Pharmaceuticals, Inc. | $412.7M | 0.0× | Compare |
| KYTX Kyverna Therapeutics, Inc. | $432.3M | 0.0× | Compare |
| ARCT Arcturus Therapeutics Holdings Inc. | $412.4M | 0.0× | Compare |
| RLMD Relmada Therapeutics, Inc. | $406.4M | 0.0× | Compare |
DiaMedica Therapeutics, Inc. (DMAC) key facts
- DiaMedica Therapeutics, Inc. (DMAC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- DiaMedica Therapeutics, Inc. reported a net loss of $32.8 million, or a loss of $0.70 per share, for fiscal 2025.
- As of September 25, 2026, DMAC traded at $7.94, a market capitalization of $422.2 million.
- Return on equity was −67.7% and debt-to-equity 0.00.
DiaMedica Therapeutics, Inc. (DMAC) Latest News
17 Aug
DiaMedica Therapeutics (DMAC) held its Q2 2026 earnings call, covering financial results, operational updates, and business outlook. Quarterly earnings calls typically provide financial and operational updates with moderate influence on near-term market sentiment.
13 Aug
DiaMedica Therapeutics (DMAC) upgraded to Buy rating. Buy rating upgrade may lift short-term DMAC stock sentiment without altering core operations.
11 Aug
DiaMedica Therapeutics Inc highlighted promising preeclampsia developments during its Q2 2026 earnings call. Promising preeclampsia pipeline updates from earnings call point to major clinical progress likely to shift company trajectory and investor sentiment.
DiaMedica Therapeutics Inc. held its Q2 2026 earnings call covering financial results, operational updates, and forward outlook for the company's development programs. Quarterly earnings call delivers financial metrics and pipeline status that can shift near-term sentiment without guaranteeing major strategic change.
DMAC held Q2 earnings call covering financial results, clinical development updates for DM199, cash position and upcoming milestones in preeclampsia and chronic kidney disease programs. Quarterly earnings updates supply routine financial and pipeline details that can move sentiment modestly but rarely shift long-term company trajectory.
10 Aug
DiaMedica Therapeutics reported second quarter 2026 financial results and provided business highlights. Quarterly financial results and updates can shift near-term investor sentiment and valuation for the company.
3 Aug
DiaMedica Therapeutics (DMAC) is positioned as a biotech company with breakthrough potential. Breakthrough potential signals major strategic or technological advances likely to shift DMAC's trajectory and investor sentiment.
23 Jun
DiaMedica Therapeutics dosed first patients in Phase 2 trial of DM199 for fetal growth restriction treatment. Phase 2 trial start advances DM199 development and may moderately affect company trajectory.
16 Jun
DiaMedica Therapeutics received FDA feedback on its DM199 nonclinical program for preeclampsia. FDA feedback on DM199 nonclinical program constitutes standard regulatory progress with moderate potential to influence development timeline and sentiment.
1 Jun
DiaMedica Therapeutics held its Q4 2025 earnings conference call, covering financial results, operational updates, and forward outlook. Quarterly earnings call supplies performance data and guidance that can shift near-term sentiment and valuation.
20 May
DiaMedica Therapeutics reaches 75% enrollment in its ReMEDy2 Phase 2/3 trial evaluating DM199 for acute ischemic stroke. 75% enrollment in the pivotal stroke trial marks steady clinical progress that may influence near-term sentiment and timelines but stops short of data or approval.
10 May
DiaMedica Therapeutics (NASDAQ:DMAC) is in a good position to deliver on its growth plans. DMAC's favorable positioning for growth execution is expected to moderately influence investor sentiment and financial outlook.
7 May
DiaMedica Therapeutics (DMAC) released Q1 earnings call highlights covering financial results, clinical trial updates, and strategic outlook. Q1 earnings call highlights offer updates on financials and clinical progress with moderate potential to influence stock sentiment and trajectory.
DiaMedica Therapeutics Inc. (DMAC) issued Q1 2026 earnings call summary covering financial results, operational updates and outlook. Routine earnings call summaries deliver financial metrics and guidance that can shift near-term investor sentiment and trading activity.
6 May
DiaMedica Therapeutics, Inc. (DMAC) reported first quarter 2026 financial results and provided business highlights. Quarterly financial results and business highlights moderately affect financial performance and investor sentiment.
16 Apr
DiaMedica Therapeutics highlighted DM199 preeclampsia data and stroke interim catalyst at RedChip Conference. Highlighting DM199 preeclampsia data and stroke interim results represents major clinical progress that could significantly alter investor sentiment and company trajectory.
31 Mar
DiaMedica Therapeutics Inc (DMAC) reported a strong cash position in its Q4 2025 earnings call, alongside key operational updates and progress in clinical programs. Strong cash position signals financial stability to fund clinical trials, significantly boosting investor confidence and stock trajectory.
DiaMedica Therapeutics Inc. (DMAC) released Q4 2025 earnings call summary detailing financial results, operational updates, and future outlook. Earnings call summary updates financial performance and business progress with moderately noticeable influence on investor sentiment and trajectory.
DiaMedica Therapeutics Inc. (DMAC) Q4 earnings call highlights financial results, clinical trial progress, operational updates, and forward-looking guidance. Q4 earnings highlights cover financials and pipeline developments with moderately noticeable influence on DMAC's performance and investor sentiment.
30 Mar
DiaMedica Therapeutics, Inc. (DMAC) reported full year 2025 financial results and provided business highlights. Full-year financial results and business highlights represent major disclosures that can significantly alter investor sentiment and the company's market trajectory.
5 Mar
DiaMedica Therapeutics Inc. (DMAC) received Health Canada clearance to initiate a Phase 2 clinical study of DM199 for preeclampsia treatment. Regulatory clearance for Phase 2 trial initiation advances DMAC's pipeline significantly, potentially enhancing investor sentiment and stock performance.
15 Feb
DiaMedica Therapeutics insiders bought US$58.4 million worth of stock, significantly increasing their holdings and signaling strong confidence in the company's prospects. Massive insider purchases of $58.4 million demonstrate high internal confidence, poised to drive positive investor sentiment and stock performance.
18 Dec
DiaMedica Therapeutics, Inc. provided an update on its DM199 preeclampsia program following a pre-Investigational New Drug (IND) meeting with the FDA. The company is advancing its clinical development plans and is optimistic about the potential of DM199 in treating preeclampsia, a serious pregnancy complication. The feedback from the FDA will guide the next steps in the program, which aims to address unmet medical needs in this area. The FDA meeting and subsequent guidance are likely to significantly influence the development and potential market entry of DM199, impacting the company's future performance.
1 Dec
DiaMedica Therapeutics, Inc. is positioned to drive business growth, supported by its financial stability and strategic initiatives. The company has sufficient resources to invest in product development and expand its market presence, which could enhance its competitive edge in the biopharmaceutical sector. Analysts express confidence in DiaMedica's ability to leverage its assets for future advancements. Strategic initiatives and financial stability are likely to significantly impact the company's growth trajectory and investor sentiment.
20 Nov
DiaMedica Therapeutics, Inc. (DMAC) is highlighted among three biotech stocks that Wall Street analysts predict will more than double in value. The company is recognized for its innovative approach to treating neurological disorders, particularly with its lead product candidate, DM199, which is in clinical trials. Analysts express optimism about the potential for significant growth, driven by positive trial results and increasing market interest in the company's therapies. Positive clinical trial results and market interest could significantly alter the company's trajectory and investor sentiment.
13 Nov
DiaMedica Therapeutics, Inc. (DMAC) reported promising clinical advances during its Q3 2025 earnings call, highlighting progress in its drug development pipeline and positive results from recent trials. The company emphasized its commitment to addressing unmet medical needs and outlined future strategies for growth and innovation. Investors showed optimism regarding the potential impact of these developments on the company's market position. Promising clinical advances and strategic growth plans are likely to significantly impact future performance and investor sentiment.
12 Nov
DiaMedica Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its pipeline and strategic initiatives, focusing on innovative therapies. Management provided insights into future growth prospects and operational strategies aimed at enhancing shareholder value. The financial results and business highlights indicate moderate progress in key areas that may influence the company's performance.
4 Nov
Insiders at DiaMedica Therapeutics Inc. (NASDAQ:DMAC) hold a 48% ownership stake and have recently increased their buying activity, indicating strong confidence in the company's future prospects. Insider buying typically reflects positive sentiment, which may moderately influence market perception and investor confidence.
17 Sep
DiaMedica Therapeutics, Inc. (DMAC) is gaining attention as a momentum stock due to its recent performance and potential for growth. Investors are considering whether to buy shares based on the company's strategic developments and market positioning. Analysts highlight the positive trends and future prospects that could enhance DMAC's value in the biotech sector. Significant strategic developments and market interest are likely to influence DMAC's future performance.
9 Sep
DiaMedica Therapeutics, Inc. (DMAC) has experienced a 'Golden Cross' in its stock chart, indicating a potential bullish trend. This technical pattern occurs when a short-term moving average crosses above a long-term moving average, suggesting increased investor interest and positive momentum. Analysts are optimistic about DMAC's future performance, citing strong fundamentals and potential growth in the biopharmaceutical sector. The company's innovative therapies and strategic initiatives are expected to enhance its market position, making it a stock to watch closely. The occurrence of a 'Golden Cross' typically signals significant positive momentum and investor interest, which can lead to substantial market performance changes.